AA
QNCX icon

ALPS Advisors’s Quince Therapeutics QNCX Stock Holding History

ALPS Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-182
Closed -$3.33M – 959
2021
Q3 		$3.33M Sell
182
-13
-7% -$207K 0.03% 203
2021
Q2 		$2.06M Sell
195
-72
-27% -$604K 0.02% 324
2021
Q1 		$1.93M Hold
267
– – 0.02% 312
2020
Q4 		$1.48M Buy
267
+79
+42% +$700K 0.02% 350
2020
Q3 		$1.88M Sell
188
-13
-6% -$118K 0.03% 243
2020
Q2 		$1.86M Sell
201
-43
-18% -$394K 0.02% 245
2020
Q1 		$2.23M Sell
244
-26
-10% -$257K 0.03% 205
2019
Q4 		$3.03M Buy
+270
New +$1.63M 0.02% 193

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

ALPS Advisors's QNCX Position: Q4 2021 in Review

ALPS Advisors sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 182 shares — an estimated $3.33M sold.

ALPS Advisors first reported a position in QNCX in Q4 2019 and held it in 8 quarters. The position peaked at $3.33M in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • ALPS Advisors reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 182 Quince Therapeutics shares in Q4 2021, an estimated $3.33M.
  • ALPS Advisors first reported a position in Quince Therapeutics in Q4 2019 and held it in 8 quarters.
  • ALPS Advisors's Quince Therapeutics position peaked at $3.33M in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.